Changjiang Ying1, Zhongyuan Zhou2, Jiao Dai2, Meng Wang2, Jie Xiang3, Dong Sun4, Xiaoyan Zhou5. 1. Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. 2. The Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, People's Republic of China. 3. Department of Rehabilitation, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. 4. Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. Sundongxz@yahoo.com. 5. Department of Genetics, School of Life Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, People's Republic of China. zhouxiaoyan0201@xzhmu.edu.cn.
Abstract
OBJECTIVE: Inflammation is central to the development and progression of diabetic nephropathy (DN). Although the exact mechanisms of inflammation in the kidney have not been well elucidated, pyrin domain containing 3 (NLRP3) inflammasome activation is involved in the onset and progression of DN. Here, we investigated the underlying regulatory mechanisms of hyperglycaemia-induced NLRP3 inflammasome activation in the kidney. METHODS: HEK293T cells received high glucose, and the cell proliferation and apoptosis were detected. Biochemical indicators in db/db mice were tested by kits, and the morphological changes in the kidney were observed using staining methods and transmission electron microscopy. The interaction of Ras-related C3 botulinum toxin substrate 1 (RAC1) and NLRP3 inflammasome in cells and in mice was assessed by co-immunoprecipitation (Co-IP) and immunofluorescence. Expression of all proteins was examined by western blotting and immunohistochemistry. In additional, the directly combination of RAC1 and NLRP3 was evaluated by GST Pulldown. RESULTS: High-glucose and hyperglycaemia conditions resulted in Ras-related C3 botulinum toxin substrate 1 (RAC1) and NLRP3 inflammasome interactions in cells and in mice. Additionally, RAC1 promoted NLRP3 inflammasome activation and then induced cell damage, and morphological and functional abnormalities in the kidney. We also observed that RAC1 activates the NLRP3 inflammasome by directly binding to NLRP3. CONCLUSION: In the present study, we confirmed that RAC1 binding to NLRP3 is sufficient to activate the NLRP3 inflammasome in the kidney and accelerate DN pathological processes. These results elucidate the upstream cellular and molecular mechanisms of NLRP3 inflammasome activation and provide new therapeutic strategies for the treatment of DN.
OBJECTIVE: Inflammation is central to the development and progression of diabetic nephropathy (DN). Although the exact mechanisms of inflammation in the kidney have not been well elucidated, pyrin domain containing 3 (NLRP3) inflammasome activation is involved in the onset and progression of DN. Here, we investigated the underlying regulatory mechanisms of hyperglycaemia-induced NLRP3 inflammasome activation in the kidney. METHODS: HEK293T cells received high glucose, and the cell proliferation and apoptosis were detected. Biochemical indicators in db/db mice were tested by kits, and the morphological changes in the kidney were observed using staining methods and transmission electron microscopy. The interaction of Ras-related C3 botulinum toxin substrate 1 (RAC1) and NLRP3 inflammasome in cells and in mice was assessed by co-immunoprecipitation (Co-IP) and immunofluorescence. Expression of all proteins was examined by western blotting and immunohistochemistry. In additional, the directly combination of RAC1 and NLRP3 was evaluated by GST Pulldown. RESULTS: High-glucose and hyperglycaemia conditions resulted in Ras-related C3 botulinum toxin substrate 1 (RAC1) and NLRP3 inflammasome interactions in cells and in mice. Additionally, RAC1 promoted NLRP3 inflammasome activation and then induced cell damage, and morphological and functional abnormalities in the kidney. We also observed that RAC1 activates the NLRP3 inflammasome by directly binding to NLRP3. CONCLUSION: In the present study, we confirmed that RAC1 binding to NLRP3 is sufficient to activate the NLRP3 inflammasome in the kidney and accelerate DN pathological processes. These results elucidate the upstream cellular and molecular mechanisms of NLRP3 inflammasome activation and provide new therapeutic strategies for the treatment of DN.
Authors: Vasudha Ahuja; Pasi Aronen; T A Pramodkumar; Helen Looker; Angela Chetrit; Aini H Bloigu; Auni Juutilainen; Cristina Bianchi; Lucia La Sala; Ranjit Mohan Anjana; Rajendra Pradeepa; Ulagamadesan Venkatesan; Sarvanan Jebarani; Viswanathan Baskar; Teresa Vanessa Fiorentino; Patrick Timpel; Ralph A DeFronzo; Antonio Ceriello; Stefano Del Prato; Muhammad Abdul-Ghani; Sirkka Keinänen-Kiukaanniemi; Rachel Dankner; Peter H Bennett; William C Knowler; Peter Schwarz; Giorgio Sesti; Rie Oka; Viswanathan Mohan; Leif Groop; Jaakko Tuomilehto; Samuli Ripatti; Michael Bergman; Tiinamaija Tuomi Journal: Diabetes Care Date: 2021-04 Impact factor: 19.112
Authors: Joe Kwun Nam Chan; Corine Sau Man Wong; Philip Chi Fai Or; Eric Yu Hai Chen; Wing Chung Chang Journal: Br J Psychiatry Date: 2021-07 Impact factor: 9.319
Authors: Liang Wu; Changjie Liu; Dong-Yuan Chang; Rui Zhan; Jing Sun; Shi-He Cui; Sean Eddy; Viji Nair; Emily Tanner; Frank C Brosius; Helen C Looker; Robert G Nelson; Matthias Kretzler; Jian-Cheng Wang; Ming Xu; Wenjun Ju; Ming-Hui Zhao; Min Chen; Lemin Zheng Journal: Kidney Int Date: 2021-03-03 Impact factor: 10.612